BPC March 26 update

TFFP offering; IPOs Edgewise EWTX and Ikena IKNA

Price and Volume Movers

Friday saw only a smattering of notable newsflow. No news was released in regard to the FDA approval decision for ide-cel, submitted by Bristol-Myers Squibb Company (NYSE:BMY) and bluebird bio, Inc. (NASDAQ: BLUE). Expect news to be released pre-market on Monday.

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) announced it intends to sell 2,140,000 shares at an offering price of $14.00 per share for gross proceeds of $40 million. Shares fell 14% to $13.03.

GlaxoSmithKline plc (NYSE:GSK) and Vir Biotechnology, Inc. (NASDAQ:VIR) announced the submission of their Emergency Use Authorization (EUA) filing with the FDA for VIR-7831 (GSK4182136), an antibody for the treatment of mild-to-moderate COVID-19 who are at risk for progression to hospitalization or death.


Major price movers (stocks priced > $1.00, volume > 50k listed on NASDAQ/NYSE):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume:


XOMA Corporation (XOMA): $39.99; +20%.

180 Life Sciences Corp. (ATNF): $6.96; +19%.

Salarius Pharmaceuticals, Inc. (SLRX): $1.56; +13%.

Instil Bio, Inc. (TIL): $27.06; +12%.

TCR2 Therapeutics Inc. (TCRR): $23.26; +11%.


Rubius Therapeutics, Inc. (RUBY): $24.62; -23%.

Immutep Limited (IMMP): $3.11; -15%.

Odonate Therapeutics, Inc. (ODT): $3.09; -14%.

ImmunityBio, Inc. (IBRX): $26.78; -13%.

Lava Therapeutics B.V. (LVTX): $12.50; -13%.

Included in the pipeline updates below are IPOs from Edgewise Therapeutics, Inc. (NASDAQ: EWTX) and Ikena Oncology, Inc (NASDAQ: IKNA). Edgewise shares closed 87.5% above its listing price of $16, while Ikena shares closed 100% higher at $32.00.

Pipeline Database Updates

Drug Stage Catalyst Market Cap

EWTX – Edgewise Therapeutics Inc.
Healthy volunteers

Phase 1 Phase 1 safety, tolerability and PK data for both the multiple ascending dose (MAD) in healthy volunteers and adult Becker muscular dystrophy patients in 2H 2021.
$1.5 billion

GSK – GlaxoSmithKline PLC
VIR-7831 / GSK4182136 (COMET-ICE)
COVID-19 antibody

Phase 3 Phase 3 data released March 10, 2021. 85% reduction in hospitalization or death. Trial to be stopped. FDA Emergency Use Authorization filing announced March 26, 2021.
$92.2 billion

IKNA – Ikena Oncology Inc.
IK-175 and nivolumab
Bladder cancer

Phase 1 Phase 1 enrollment to be completed 2H 2022.
$555.1 million

IKNA – Ikena Oncology Inc.
Colorectal cancer

Phase 1b Phase 1b enrollment to be completed 2H 2021.
$555.1 million